Introduction
============

T-cell acute lymphoblastic leukemia (T-ALL), an aggressive malignancy arising from T-cell progenitors, accounts for \~15% of ALL cases in children and \~25% in adults. The long-term survival rate for children and adolescents with this disease is 70--75%, while for adults the rate is only 35--40% in Western populations ([@b1-ol-08-03-1355]). Over 50% of patients with T-ALL harbor activation mutations of Notch1 ([@b2-ol-08-03-1355]), thus, γ-secretase inhibitors, which block Notch signaling, were a promising target for therapy. However, associated problems, such as limited therapeutic benefit and intestinal toxicity have since been reported ([@b3-ol-08-03-1355]). Therefore, there is a requirement for the development of novel and effective treatment strategies for adult T-ALL.

Notch1 mutations mainly involve the heterodimerization domain (HD) and the proline, glutamic acid, serine, threonine-rich domain (PEST) ([@b2-ol-08-03-1355]). The HD mutation results in ligand-independent proteolytic cleavage of Notch1, while the PEST mutation blocks Fbw7 interaction with Notch1 and, thereby, prevents its polyubiquitination and degradation ([@b3-ol-08-03-1355],[@b4-ol-08-03-1355]). The mutations of these two domains result in constitutive activation of the Notch signaling pathway ([@b1-ol-08-03-1355]). Moreover, \~30% of T-ALL patients harbor inactivating mutations of the Fbw7 gene, which also activate Notch1 signaling ([@b1-ol-08-03-1355]). It has been demonstrated that c-Myc is a direct and important target gene of Notch1, and its expression levels have been observed to increase along with activation of Notch1 signaling in T-ALL ([@b5-ol-08-03-1355]). In addition, a previous study showed that the half-life of c-Myc in B-cell or T-cell ALL was markedly prolonged ([@b6-ol-08-03-1355]). Therefore, c-Myc may be a target for therapy in T-ALL.

Valproic acid (VPA), a histone deacetylase inhibitor (HDACI), has been reported to treat various hematological malignancies ([@b7-ol-08-03-1355]--[@b9-ol-08-03-1355]). Previous studies revealed that VPA was more efficacious in combination with other agents, such as idarubicin, 5-azacitidina and all-trans retinoic acid ([@b10-ol-08-03-1355]--[@b12-ol-08-03-1355]). In acute myeloid leukemia (AML), VPA inhibited cell growth, mainly by downregulation of c-Myc expression ([@b13-ol-08-03-1355]). However, the role of c-Myc in the growth inhibition of T-ALL cells induced by VPA remains unclear. We hypothesized that its role in T-ALL was the same as that in AML, and that a c-Myc inhibitor would be able to augment the anti-leukemic effect of VPA. In the present study, the effect of VPA combined with a c-Myc inhibitor (10058-F4) on T-ALL cell lines (Jurkat and CCRF-CEM cells) was investigated.

Materials and methods
=====================

Cell lines and reagents
-----------------------

T-ALL cell lines, Jurkat and CCRF-CEM cells, were purchased from the American Type Culture Collection (Manassas, VA, USA). These cells were maintained in RPMI-1640 (Gibco-BRL, Grand Island, NY, USA) supplemented with heat-inactivated fetal bovine serum (Gibco-BRL) at 37°C in a 5% CO~2~ humidified incubator. VPA and 10058-F4 (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in dimethylsulfoxide (DMSO) at 1 M and 20 mM and then stored at −20°C in small aliquots. Z-VAD-FMK (Sigma-Aldrich), a pan-caspase inhibitor ([@b14-ol-08-03-1355]), was also dissolved in DMSO and its final concentration was 20 μM.

Cell viability assay
--------------------

Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) assay. Briefly, cells were seeded in 96-well plates and treated with VPA (0--3.2 mM), alone or in combination with 60 μM 10058-F4, for 24 h. In each well, MTT solution (final concentration, 0.5 mg/ml) was added and the cells were then incubated at 37°C for 4 h. The absorbance value of each well was measured by a spectrophotometry at 570 nm.

Flow cytometry
--------------

Cell death was detected by Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) (BD Pharmingen, San Diego, CA, USA) staining. Cells were treated with VPA (0--2.4 mM), with or without 60 μM 10058-F4, for 24 h. Cells were collected in a tube using pipet tips, washed twice in 4°C PBS and then resuspended in 50 μl Annexin V binding buffer (BD Pharmingen). Subsequently, 5 μl Annexin V-FITC and 5 μl PI were added, and these samples were incubated in the dark at 25°C for 15 min. Following the addition of 450 μl Annexin V binding buffer, cell death in the samples was measured on a FACScanto™ II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).

Quantitative polymerase chain reaction (qPCR)
---------------------------------------------

The expression level of the c-MYC gene was determined using reverse transcription-qPCR with SYBR Green I \[Takara Biotechnology (Dalian) Co., Ltd., Dalian, China\], and GAPDH was used as a reference gene. Total RNA was extracted using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA) and reverse transcribed into cDNA by a SuperScript II first-strand cDNA synthesis kit (Invitrogen Life Technologies). The reaction system contained 12.5 μl 2X SYBR Premix Ex Taq \[Takara Biotechnology (Dalian) Co., Ltd.\], 1 μl cDNAs and 10 pmol of each primer. The primer sequences were as follows: Forward, 5′-ATGGGGAAGGTGAAGGTCG-3′ and reverse, 5′-GGGTCATTGATGGCAACAATATC-3′ for GAPDH; and forward, 5′-CGTCTCCACACATCAGCACAA-3′ and reverse, 5′-CACTGTCCAACTTGACCCTCTTG-3′ for c-MYC. The reaction was performed at 95°C for 1 min, followed by 40 cycles of denaturation at 95°C for 15 sec and annealing/extension at 60°C for 60 sec, on an iQ5 Real-Time PCR instrument (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Western blot
------------

Jurkat and CCRF-CEM cells were lysed at 0°C in lysis buffer for 30 min, and their protein concentrations were measured by the Bradford protein assay method. The samples were separated by 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and then transferred onto polyvinylidene fluoride (PVDF) membranes. PVDF membranes were blocked with Tris-buffered saline containing 0.1% Tween (TBST; prepared in the laboratory, Department of Hematology, Institute of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China) and 5% non-fat milk for 2 h at room temperature. The membranes were then incubated with the primary antibodies, rabbit anti-human monoclonal c-Myc (D84C12 XP^®^), rabbit anti-human monoclonal caspase-3 (8G10) and mouse anti-human monoclonal β-actin (8H10D10) (dilution, 1:1000--5000; Cell Signaling Technology, Beverly, MA, USA), overnight at 4°C. Following washing four times for 10 min each time with TBST, these PVDF membranes were incubated with the goat anti-rabbit (catalogue number, 7074) or horse anti-mouse (catalogue number, 7076) IgG horseradish peroxidase-conjugated secondary antibodies (dilution, 1:2000; Cell Signaling Technology) for 2 h at room temperature. The membranes were again washed four times with TBST, and protein bands were then visualized with the enhanced chemiluminescence detecting kit (EZ-ECL chemiluminescence detection kit; Biological Industries, Beit-Haemek, Israel) and exposed to X-ray films.

Statistical analysis
--------------------

The significant differences between experimental and control groups were compared by Student's t-test. P\<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA).

Results
=======

VPA downregulates the expression of c-Myc in Jurkat and CCRF-CEM cells
----------------------------------------------------------------------

First, the role of c-Myc in the growth inhibition of T-ALL cells induced by VPA was identified. Western blots revealed that after Jurkat and CCRF-CEM cells were treated with VPA at various concentrations for 24 h, the expression of c-Myc protein was markedly downregulated in a dose-dependent manner, and was accompanied by cleavage of caspase-3 ([Fig. 1A](#f1-ol-08-03-1355){ref-type="fig"}). qPCR was then performed to measure the c-Myc mRNA levels, and it was found that the expression of c-Myc was also decreased in Jurkat and CCRF-CEM cells treated with 0.8 mM VPA for 24 h ([Fig. 1B](#f1-ol-08-03-1355){ref-type="fig"}; P\<0.01), indicating that c-Myc was downregulated at a transcriptional level. In addition, decreased expression of c-Myc protein in a time-dependent manner was observed in Jurkat cells ([Fig. 1C](#f1-ol-08-03-1355){ref-type="fig"}), but not examined in CCRF-CEM cells.

10058-F4 further promotes downregulation of c-Myc expression by VPA
-------------------------------------------------------------------

It has been demonstrated that 10058-F4 can block the dimerization of c-Myc and Max, and then inhibit c-Myc transactivating activity ([@b15-ol-08-03-1355]). Thus, we hypothesized that 10058-F4 promotes the downregulation of c-Myc expression induced by VPA. The western blotting results showed that c-Myc expression levels in Jurkat and CCRF-CEM cells treated with VPA (0, 0.8 and 1.6 mM) combined with 60 μM 10058-F4 decreased further compared with the corresponding controls ([Fig. 2](#f2-ol-08-03-1355){ref-type="fig"}).

10058-F4 increases the growth inhibition of Jurkat and CCRF-CEM cells induced by VPA
------------------------------------------------------------------------------------

c-Myc is an important oncogene, which contributes to the growth of T-ALL cells, particularly T-ALL cells with Notch1 mutations ([@b5-ol-08-03-1355]). The present study results showed that 10058-F4 and VPA synergistically downregulated c-Myc expression in Jurkat and CCRF-CEM cells. It was next investigated whether 10058-F4 could increase cell growth inhibition induced by VPA in Jurkat and CCRF-CEM cells, by MTT assay. The growth inhibition rates of Jurkat cells treated with VPA (0, 0.8, 1.6 and 2.4 mM) combined with 10058-F4 for 24 h were 17.06±1.03, 47.99±4.35, 51.70±6.19 and 65.27±6.86% respectively, which were significantly higher than those treated with corresponding concentrations of VPA (0, 4.28±0.13, 11.21±4.46 and 17.86±2.60%) (P=0.012). In CCRF-CEM cells, the growth inhibition rates for VPA (0, 0.8, 1.6 and 2.4 mM) plus 10058-F4 were 23.80±3.37, 55.76±3.72, 64.65±2.48 and 68.60±3.48%, respectively, which were also significantly higher than those for the corresponding concentrations of VPA alone (0, 7.92±2.62, 17.03±4.54 and 17.42±3.42%) (P=0.007) ([Fig. 3](#f3-ol-08-03-1355){ref-type="fig"}).

10058-F4 markedly increases the cell death induced by VPA in a caspase-dependent and -independent manner
--------------------------------------------------------------------------------------------------------

Previous studies have demonstrated that 10058-F4 efficiently induced cell death in myeloma and AML cells ([@b15-ol-08-03-1355],[@b16-ol-08-03-1355]). Concordant with this, cell death of Jurkat and CCRF-CEM cells treated with VPA (0, 0.8, 1.6 and 2.4 mM) was increased when combined with 10058-F4. As shown in [Fig. 4A](#f4-ol-08-03-1355){ref-type="fig"}, compared with treatment with corresponding concentrations of VPA alone, cell death rates (Annexin V^+^/PI^+^ and Annexin V^+^/PI^-^) of Jurkat and CCRF-CEM cells treated with 10058-F4 combined with VPA increased significantly (P=0.038 and P=0.037, respectively). In addition, western blot analysis revealed that 10058-F4 could promote the cleavage of caspase-3 induced by VPA ([Fig. 4B](#f4-ol-08-03-1355){ref-type="fig"}). The results also demonstrated that Z-VAD-FMK, a pan-caspase inhibitor, could partially inhibit cell death of Jurkat cells induced by 10058-F4 combined with VPA (72.33±3.35 vs. 37.4±1.87%, P\<0.001) ([Fig. 4C](#f4-ol-08-03-1355){ref-type="fig"}). These findings indicate that 10058-F4 dramatically increases cell death induced by VPA through caspase-dependent and -independent pathways.

Discussion
==========

It has been demonstrated that VPA could prevent growth of cancer cells by inducing apoptosis and cell cycle arrest, and by promoting cellular differentiation ([@b17-ol-08-03-1355]). HDACIs, including VPA, can selectively alter the expression levels of a relatively small proportion of genes by recovering the deacetylation of histones ([@b18-ol-08-03-1355]). Regarding these genes in which the expression levels are altered by HDACIs, upregulation of the surface TRAIL death receptors (DR4 and DR5) in multiple myeloma ([@b19-ol-08-03-1355]), upregulation of p21 and p27 in mantle cell lymphoma ([@b20-ol-08-03-1355]), and downregulation of c-Myc in AML and endometrial cancer cells ([@b13-ol-08-03-1355],[@b21-ol-08-03-1355]) played a key role in the induction of apoptosis and cell cycle arrest or the promotion of cellular differentiation.

Since activating mutations of Notch1 were observed in \>50% T-ALL patients ([@b3-ol-08-03-1355]) and c-Myc is an important direct target of Notch1 ([@b5-ol-08-03-1355]), the present study examined whether c-Myc was downregulated in the growth inhibition of T-ALL cells induced by VPA. The results showed that, as in AML ([@b13-ol-08-03-1355]), c-Myc expression was markedly downregulated in Jurkat and CCRF-CEM cells in which activation of Notch1 signaling occurred ([@b22-ol-08-03-1355]). Further investigation revealed that 10058-F4 could reinforce the downregulation of c-Myc induced by VPA, indicating that the former may increase the sensitivity to the latter.

Previous studies have demonstrated that VPA can induce apoptosis in leukemic cells ([@b7-ol-08-03-1355],[@b23-ol-08-03-1355]). Notably, VPA also augmented apoptosis of leukemic cells induced by other agents, such as cytarabine ([@b24-ol-08-03-1355]), etoposide ([@b25-ol-08-03-1355]) and bortezomib ([@b26-ol-08-03-1355]). Thus, the present study next examined the cell death of Jurkat and CCRF-CEM cells induced by VPA combined with 10058-F4. The results showed that 10058-F4 could markedly increase the cell death of Jurkat and CCRF-CEM cells induced by VPA (0, 0.8, 1.6 and 2.4 mM). Activation of caspase-3 also increased correspondingly. However, Z-VAD-FMK partially inhibited the cell death induced by 10058-F4 combined with VPA, indicating that their apoptotic effects involved in both caspase-dependent and -independent pathways. Previous studies have also demonstrated that not only 10058-F4, but also VPA, induced apoptosis through both caspase-dependent and -independent pathways ([@b15-ol-08-03-1355],[@b23-ol-08-03-1355],[@b27-ol-08-03-1355]).

Although there have been arguments for and against the therapeutic targeting of Myc ([@b28-ol-08-03-1355]), recent experiments *in vivo* and *in vitro* have demonstrated that it is a promising therapeutic strategy in high-risk hematologic malignancies ([@b29-ol-08-03-1355],[@b30-ol-08-03-1355]). The present study showed that downregulation of c-Myc by 10058-F4 markedly increased VPA-induced apoptosis. These findings suggest that VPA combined with c-Myc inhibitors may be a novel potent therapeutic strategy for adult T-ALL patients. However, further investigation with regard to the clinical effect of their combination is required in the future.
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![Influence of VPA on the expression levels of c-Myc. (A) Level of c-Myc protein varied in Jurkat and CCRF-CEM cells exposed to 0.8, 1.6, 2.4 and 3.2 mM VPA. (B) Level of c-Myc mRNA varied in Jurkat and CCRF-CEM cells exposed to 0.8 mM VPA. (C) Level of c-Myc protein varied in Jurkat cells exposed to 0.8 mM VPA for 6, 12, 24 and 48 h. ^\*\*^P\<0.01. VPA, valproic acid.](OL-08-03-1355-g00){#f1-ol-08-03-1355}

![Levels of c-Myc protein in Jurkat and CCRF-CEM cells exposed to VPA combined with 10058-F4 for 24 h. VPA, valproic acid.](OL-08-03-1355-g01){#f2-ol-08-03-1355}
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![Cell death of Jurkat and CCRF-CEM cells induced by VPA combined with 10058-F4. (A) Cell death was examined by dual staining with Annexin V/PI in Jurkat and CCRF-CEM cells treated with VPA combined with 10058-F4 (60 μM) for 24 h (mean ± SD; n=3). (B) The level of cleaved caspase-3 varied after exposure of cells to VPA combined with 60 μM 10058-F4. Bar graphs were plotted according to the densitometry of the cleaved caspase-3/β-actin band densities (mean ± SD; n=3). (C) Cell death induced by VPA (2.4 mM) combined with 10058-F4 (60 μM) in Jurkat cells was partially inhibited by Z-VAD-FMK (20 μM) (mean ± SD; n=3). ^\*\*^P\<0.01 for all concentrations of VPA. VPA, valproic acid; PI, propidium iodide; Z, Z-VAD-FMK.](OL-08-03-1355-g03){#f4-ol-08-03-1355}
